Nurix Therapeutics (NRIX) – Research Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Nurix Therapeutics (NASDAQ: NRIX) in the last few weeks:

• 1/29/2025 – Nurix Therapeutics had its price target lowered by analysts at JPMorgan Chase & Co. from $31.00 to $30.00. They now have an “overweight” rating on the stock.
• 1/29/2025 – Nurix Therapeutics had its price target raised by analysts at Royal Bank of Canada from $26.00 to $27.00. They now have an “outperform” rating on the stock.
• 1/29/2025 – Nurix Therapeutics had its price target raised by analysts at HC Wainwright from $35.00 to $36.00. They now have a “buy” rating on the stock.
• 1/29/2025 – Nurix Therapeutics had its price target lowered by analysts at Needham & Company LLC from $29.00 to $28.00. They now have a “buy” rating on the stock.
• 1/29/2025 – Nurix Therapeutics had its price target raised by analysts at Stifel Nicolaus from $34.00 to $36.00. They now have a “buy” rating on the stock.
• 1/21/2025 – Nurix Therapeutics had its “overweight” rating reaffirmed by analysts at Stephens. They now have a $31.00 price target on the stock.
• 12/11/2024 – Nurix Therapeutics had its price target raised by analysts at HC Wainwright from $30.00 to $35.00. They now have a “buy” rating on the stock.
• 12/10/2024 – Nurix Therapeutics is now covered by analysts at BTIG Research. They set a “buy” rating and a $35.00 price target on the stock.
• 12/10/2024 – Nurix Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
• 12/6/2024 – Nurix Therapeutics is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $35.00 price target on the stock.

Nurix Therapeutics Stock Down 1.5 %

NRIX opened at $19.71 on Monday. The business has a 50 day moving average price of $20.05 and a two-hundred day moving average price of $22.36. The company has a market cap of $1.50 billion, a PE ratio of -6.82 and a beta of 2.14. Nurix Therapeutics, Inc. has a 52 week low of $7.79 and a 52 week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 63.38%. As a group, sell-side analysts expect that Nurix Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Houte Hans Van sold 2,811 shares of Nurix Therapeutics stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $55,798.35. Following the completion of the sale, the chief financial officer now owns 39,549 shares of the company’s stock, valued at $785,047.65. The trade was a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gwenn Hansen sold 3,690 shares of Nurix Therapeutics stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the transaction, the insider now owns 55,937 shares in the company, valued at $1,110,349.45. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. 7.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Amalgamated Bank increased its holdings in Nurix Therapeutics by 30.6% in the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after buying an additional 511 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Nurix Therapeutics by 31.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after purchasing an additional 559 shares during the last quarter. Quarry LP grew its holdings in shares of Nurix Therapeutics by 3,746.2% during the third quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $56,000 after purchasing an additional 2,435 shares during the last quarter. International Assets Investment Management LLC grew its holdings in shares of Nurix Therapeutics by 1,098.4% during the third quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after purchasing an additional 4,119 shares during the last quarter. Finally, Quest Partners LLC grew its holdings in shares of Nurix Therapeutics by 21.3% during the third quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after purchasing an additional 1,312 shares during the last quarter.

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.